Immune checkpoint inhibitors have revolutionized the treatment landscape for bladder cancer and upper tract urothelial carcinoma (UTUC). Initially confined to advanced disease, the anti-PD-1…
Idiopathic pulmonary fibrosis (IPF) is a chronic lung disorder associated with progressive inflammation and/or fibrosis of the lung tissue. The leading cause of the disorder is unknown. IPF…
TNF-alpha inhibitors (Johnson & Johnson Innovative Medicine’s Remicade, AbbVie’s Humira), a CAM inhibitor (Takeda’s Entyvio), and an IL-12/23 inhibitor (Johnson & Johnson Innovative Medicine’s…
Obesity is recognized as a chronic disease and public health concern globally. The primary goals of obesity treatment are to improve patients’ health outcomes and quality of life. Physicians…
The multi-billion-dollar non-small-cell lung cancer (NSCLC) market is highly dynamic, with a plethora of approved therapies but still a high unmet need. Immune checkpoint inhibitors such as…
Hemophilia B is a genetic disorder caused by a deficiency in clotting factor IX. Current treatment is dominated by factor IX replacement therapies (in noninhibitor patients) and bypass agents (in…
Relapsed / refractory (R/R) Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL) patients have a poor prognosis. No standard of care has been established for relapsed / refractory…
Painful diabetic neuropathy (PDN) is a prevalent complication of chronic diabetes, inducing enduring and often intense pain, characterized by sensations of burning, stabbing, tingling, and…
Painful diabetic neuropathy (PDN) is a prevalent complication of chronic diabetes, inducing enduring and often intense pain, characterized by sensations of burning, stabbing, tingling, and…
Treatment of chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU) is dominated by oral medications—both approved (e.g., first- and second-generation antihistamines) and…
Type 2 diabetes (T2D) remains one of the biggest public health concerns in China, where the disease’s prevalence is globally the highest. Biguanides and alpha-glucosidase inhibitors continue to…
The landmark FDA approval of Biogen / Eisai’s aducanumab (Aduhelm) in 2021 has had a minimal effect on treatment dynamics in AD owing to the lack of reimbursement and the controversy surrounding…
Although multiple guidelines recommend treating post-traumatic stress disorder (PTSD) with psychotherapy first, such an approach does not suffice for many patients, necessitating the use of…
Migraine, which afflicts approximately 73 million people in the major pharmaceutical markets, according to Clarivate Epidemiology, is a heterogeneous condition requiring individualized treatment…